The Technical Analyst
Viking Therapeutics Inc [VKTX]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Viking Therapeutics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
0.22% $65.07
America/New_York / 24 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 7 115.79 mill |
| EPS: | -0.910 |
| P/E: | -71.51 |
| Earnings Date: | Apr 23, 2024 |
| SharesOutstanding: | 109.36 mill |
| Avg Daily Volume: | 6.46 mill |
| RATING 2024-04-24 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Sell | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | |||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -71.51 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -12.16x |
| Company: PE -71.51 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.575 (-99.12%) $-64.49 |
| Date: 2024-04-24 |
| Expected Trading Range (DAY) |
|---|
|
$ 57.89 - 72.25 ( +/- 11.03%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-27 | Mancini Marianna | Buy | 31 667 | Common Stock, par value $0.00001 per share |
| 2024-03-27 | Mancini Marianna | Sell | 16 610 | Common Stock, par value $0.00001 per share |
| 2024-03-27 | Lian Brian | Buy | 221 667 | Common Stock, par value $0.00001 per share |
| 2024-03-27 | Lian Brian | Sell | 153 948 | Common Stock, par value $0.00001 per share |
| 2024-03-27 | Zante Greg | Buy | 31 667 | Common Stock, par value $0.00001 per share |
| INSIDER POWER |
|---|
| 10.05 |
| Last 100 transactions |
| Buy: 2 960 710 | Sell: 2 536 561 |
Forecast:
16:00 - $65.13
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $65.13
Forecast 2: 16:00 - $65.13
Forecast 3: 16:00 - $65.13
SCORE
-10.00
Sell
-10.00
Sell
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $65.07 (0.22% ) |
| Volume | 2.53 mill |
| Avg. Vol. | 6.46 mill |
| % of Avg. Vol | 39.23 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For VKTX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $28.41 | N/A | Active |
|---|
VKTX
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Latest Press Releases
2024-04-24 16:05:00 - Press Release
Viking Therapeutics Reports First Quarter 2024 Financial Results And Provides Corporate Update
Conference call scheduled for 4:30 p.m. et today results from phase 2 venture trial of glp-1/gip agonist vk2735 in obesity demonstrated up to 13.1% placebo-adjusted weight loss (14.7% from baseline) at 13 weeks; shown to be safe and well-tolerated results from phase 1 trial of oral vk2735 demonstrated promising safety and tolerability with up to 3.3% placebo-adjusted weight loss (5.3% from baseline) at 28 days 52-week histology results from phase 2b voyage study evaluating vk2809 for the treatment of nash and fibrosis expected in 2q24 completed public offering of common stock raising gross proceeds of approximately $630 million ; quarter-end cash position of $963 million san diego , april 24, 2024 /prnewswire/ -- viking therapeutics, inc...
2024-04-17 16:05:00 - Press Release
Viking Therapeutics To Report Financial Results For First Quarter 2024 On April 24, 2024
Conference call scheduled for wednesday, april 24 at 4:30 p.m. eastern time san diego , april 17, 2024 /prnewswire/ -- viking therapeutics, inc. ("viking") (nasdaq: vktx), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the first quarter 2024 after the market close on wednesday, april 24, 2024.
2024-04-05 08:50:00 - Press Release
Viking Files Registration Statement With Sec For Proposed Initial Public Offering
Los angeles, april 5, 2024 /prnewswire/ -- viking holdings ltd ("viking") today announced that it has publicly filed a registration statement on form f-1 with the u.s. securities and exchange commission (the "sec") relating to a proposed initial public offering of its ordinary shares. the number of ordinary shares to be offered and the price range for the proposed offering have not yet been determined.
2024-03-26 07:03:00 - Press Release
Viking Therapeutics Announces Results From Phase 1 Clinical Trial Of Oral Tablet Formulation Of Dual Glp-1/gip Receptor Agonist Vk2735
Up to 3.3% placebo-adjusted mean weight loss (5.3% from baseline) observed after 28 days vk2735 shown to be safe and well-tolerated in 28-day study with low rates of gi-related adverse events phase 2 trial in obesity planned for 2h24 conference call scheduled for 8:00 a.m. et today san diego , march 26, 2024 /prnewswire/ -- viking therapeutics, inc. ("viking") (nasdaq: vktx), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced positive results from the company's phase 1 multiple ascending dose (mad) clinical trial of an oral tablet formulation of vk2735, a dual agonist of the glucagon-like peptide 1 (glp-1) and glucose-dependent insulinotropic polypeptide (gip) receptors, in development for the potential treatment of metabolic disorders such as obesity.
2024-03-04 16:45:00 - Press Release
Viking Therapeutics Announces Closing Of Public Offering Of Common Stock Including Full Exercise Of Underwriters' Option To Purchase Additional Shares
San diego , march 4, 2024 /prnewswire/ -- viking therapeutics, inc. ("viking") (nasdaq: vktx), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the closing of its previously announced underwritten public offering of 7,441,650 shares of its common stock at a price to the public of $85.00 per share, which included the exercise in full by the underwriters of their option to purchase up to 970,650 additional shares of common stock. the gross proceeds to viking from this offering were approximately $632.5 million, before deducting underwriting discounts and commissions and offering expenses.
Latest News
2024-04-24 11:36:46 - InvestorPlace
3 Biotech Stocks With Skyrocketing Potential: April 2024
Investing in biotech stocks is not for the faint of heart. The sector is prone to wild swings in stock prices, offering a distinctive blend of high risk and high reward.
2024-04-23 09:15:00 - The Motley Fool
Better Buy: Pfizer vs. Viking Therapeutics
Shares of Pfizer and Viking Therapeutics have been on markedly different trajectories over the prior three years. In this comparison, Pfizer scans as a safer choice for cautious investors, while Viking Therapeutics may appeal to risk-tolerant growth investors.
2024-04-22 06:05:34 - MarketBeat
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
The GLP-1 weight loss trend continues to flourish, and the ante keeps rising. The reigning champions in the battle of the bulge are Novo Nordisk A/V NYSE: NVO with its Semaglutide medications Ozempic and Wegovy, and Eli Lilly & Co. NYSE: LLY with its Tirzepatide medications Mounjaro and Zepbound.
2024-04-19 18:51:32 - Zacks Investment Research
Viking Therapeutics, Inc. (VKTX) Suffers a Larger Drop Than the General Market: Key Insights
Viking Therapeutics, Inc. (VKTX) concluded the recent trading session at $63.42, signifying a -1.93% move from its prior day's close.
2024-04-16 19:09:00 - Market Watch
Big pharma is looking to fatten profits with buyouts of weight-loss drug companies. Here are 4 candidates.
A couple of big-picture trends in biotech could add up to a nice investment opportunity. First, corporate buyouts are back in style.
2024-04-16 13:19:09 - InvestorPlace
These 3 Biotech Stocks Are Up 269% in 2024. Is There More to Come?
Investors looking for a white-knuckle ride can easily find one by buying biotech stocks. There is a certain thrill in investing in a company making actual life-or-death decisions with drugs.
2024-04-13 08:47:00 - The Motley Fool
3 Magnificent Stocks That Could Double or More by 2030
CRISPR Therapeutics has significant upside potential. Eli Lilly could become an even bigger healthcare giant.
2024-04-12 06:25:00 - InvestorPlace
Shed the Fat, Gain the Profits: 3 Weight-Loss Stocks to Own Until 2027
Weight-loss stocks remain the focus of many investors. The GLP-1 drugs that many companies have put forward address key health concerns like obesity and diabetes, which have become epidemics in many Western countries.
2024-04-11 13:49:13 - InvestorPlace
If You Can Only Buy One Biotech Stock in April, It Better Be One of These 3 Names
Biotech stocks are one of the hottest investing opportunities in the stock marketlately. The optimism surrounding the industry is evident in the SPDR S&PBiotech ETF's (NYSEARCA: XBI ) 25% bump in value over the past six months, outpacing broader market gains.
2024-04-10 09:27:00 - Market Watch
This weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives?
A new exchange-traded fund needs an edge to attract investors. This might be its industry focus — a tall order in a crowded market with ETFs covering just about any industry you can imagine.